A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome
Epilepsia · 2026-07 · 67 (7) · 3420-3431
DOI: 10.1002/epi.70216 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 27.03.2026. Verfasst von Renzo Guerrini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience and Human Genetics Department, Meyer Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Florence, Italy. Hauptthemen laut MEDLINE: Anticonvulsants, Lennox Gastaut Syndrome, Cholesterol 24-Hydroxylase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Development Center Americas, Inc., Takeda Development Center Americas.
Abstract (Originalsprache)
Objective
There remains a need for new treatments for Lennox–Gastaut syndrome (LGS), a developmental and epileptic encephalopathy with a heterogenous patient population that often requires polytherapy. The phase 3, randomized SKYWAY study (NCT04938427) investigated the efficacy and safety of the cholesterol 24‐hydroxylase inhibitor soticlestat (TAK‐935) in participants with LGS.
Methods
This global, double‐blind, placebo‐controlled trial enrolled participants aged 2–55 years with LGS (adjudicated by the Epilepsy Study Consortium). Participants were randomized 1:1 to stable background medication plus either soticlestat (≤300 mg twice daily, weight‐adjusted) or placebo over 16 weeks (4‐week titration plus 12‐week maintenance). The primary endpoint was percentage change from baseline in major motor drop (MMD) seizure frequency per 28 days.
Results
SKYWAY enrolled 270 participants (placebo, n = 136; soticlestat, n = 134); mean age was 12.9 years; 95% were receiving ≥2 antiseizure medications. The difference in median change from baseline in MMD seizure frequency for soticlestat versus placebo was −1.17% ( p = .785) during the full treatment period and 2.43% ( p = .778) during maintenance. No meaningful difference was observed between soticlestat and placebo for most key secondary endpoints; numerical trends for small effects favoring soticlestat were seen in the proportions of participants showing improvement in the Clinical Global Impression of Improvement (CGI‐I) Non‐seizure Symptoms Disruptive Behaviors domain (odds ratio = 1.91, nominal p = .032) and CGI‐I Seizure Intensity and Duration (odds ratio = 1.67, nominal p = .029). Treatment‐related adverse events (TEAEs; mostly mild or moderate) were reported in 68.4% of placebo‐treated and 74.6% of soticlestat‐treated participants; the most frequent treatment‐related TEAE with soticlestat was somnolence. Serious treatment‐related TEAEs occurred in one placebo‐treated and three soticlestat‐treated participants. Significance Soticlestat did not demonstrate efficacy versus placebo in reducing MMD seizure frequency; the safety findings were consistent with those of previous studies. These data suggest that targeting cholesterol 24‐hydroxylase is not a suitable pharmacotherapeutic strategy for LGS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience and Human Genetics Department, Meyer Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Florence, Italy.
- University of Florence, Florence, Italy.
- Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Departments of Neurology and Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Institute of Neuroscience, Guangzhou Medical University, Guangzhou, China.
- National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
ORCID-Profile: Renzo Guerrini, Eric D Marsh, Wei-Ping Liao, Cecil D Hahn, Stéphane Auvin, Mahnaz Asgharnejad, Dennis Dlugos, Venkatesha Murthy
Förderung
- Takeda Development Center Americas, Inc.
- Takeda Development Center Americas
Zitieren
APA
Guerrini, R., Marsh, E. D., Liao, W. P., Imai, K., Kravljanac, R., Altmann, A., Hahn, C. D., Auvin, S., Schiemann, J., Khan, Y., Mitra, P., Sheikh, S. I., von Rosenstiel, P., Asgharnejad, M., Dlugos, D., & Murthy, V. (2026). A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome. Epilepsia, 67(7), 3420-3431. https://doi.org/10.1002/epi.70216
Vancouver
Guerrini R, Marsh ED, Liao WP, Imai K, Kravljanac R, Altmann A, et al. A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome. Epilepsia. 2026;67(7):3420-3431. doi:10.1002/epi.70216
BibTeX
@article{Guerrini2026,
author = {Guerrini, Renzo and Marsh, Eric D and Liao, Wei-Ping and Imai, Katsumi and Kravljanac, Ruzica and Altmann, Anna and Hahn, Cecil D and Auvin, Stéphane and Schiemann, Jimmy and Khan, Yasir and Mitra, Pranab and Sheikh, Sarah I and von Rosenstiel, Philipp and Asgharnejad, Mahnaz and Dlugos, Dennis and Murthy, Venkatesha},
title = {A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome},
journal = {Epilepsia},
year = {2026},
volume = {67},
number = {7},
pages = {3420--3431},
doi = {10.1002/epi.70216}
}
EUVIMED